Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome  by Jin, Xiongjie et al.
Cell Metabolism
ArticleHeat Shock Transcription Factor 1 Is a Key
Determinant of HCC Development by Regulating
Hepatic Steatosis and Metabolic Syndrome
Xiongjie Jin,1,2,3 Demetrius Moskophidis,1,2,* and Nahid F. Mivechi1,2,3,*
1Center for Molecular Chaperone/Radiobiology and Cancer Virology, Georgia Health Sciences University, 1410 Laney Walker Boulevard,
CN-3141, Augusta, GA 30912, USA
2GHSU Cancer Center, 1410 Laney Walker Boulevard, CN-3141, Augusta, GA 30912, USA
3Charlie Norwood VA Medical Center, 1 Freedom Way, Augusta, GA 30904, USA
*Correspondence: dmoskophidis@georgiahealth.edu (D.M.), nmivechi@georgiahealth.edu (N.F.M.)
DOI 10.1016/j.cmet.2011.03.025SUMMARY
Hepatocellular carcinoma (HCC) occurrence and
progression are linked tightly to progressive hepatic
metabolic syndrome associated with insulin resis-
tance, hepatic steatosis, and chronic inflammation.
Heat shock transcription factor 1 (HSF1), a major
transactivator of stress proteins, increases survival
by protecting cells against environmental stressors.
It has been implicated in the pathogenesis of cancer,
but specific mechanisms by which HSF1 supports
cancer development remain elusive. We propose
a pathogenic mechanism whereby HSF1 activation
promotes growth of premalignant cells and HCC
development by stimulating lipid biosynthesis and
perpetuating chronic hepatic metabolic disease
induced by carcinogens. Our work shows that inacti-
vation of HSF1 impairs cancer progression, miti-
gating adverse effects of carcinogens on hepatic
metabolism by enhancing insulin sensitivity and
sensitizing activation of AMP-activated protein
kinase (AMPK), an important regulator of energy
homeostasis and inhibitor of lipid synthesis. HSF1 is
a potential target for the control of hepatic steatosis,
hepatic insulin resistance, and HCC development.
INTRODUCTION
Cancer arises through a multistage process involving selection
of genetic and epigenetic alterations, allowing evasion of mech-
anisms that limit cell proliferation or cell death (Hanahan and
Weinberg, 2011; Luo et al., 2009). In addition to genetic changes,
tumor formation and progression are regulated by the tumor
microenvironment and extracellular signaling pathways. In
particular, inflammation through aberrant secretion of cytokines
and chemokines and other progrowth factors supports prolifer-
ation and expansion of premalignant cells (Grivennikov et al.,
2010; Mantovani et al., 2008). Moreover, metabolic changes
driven by the tumor microenvironment and oncogene activation
or tumor suppressor gene loss also confer a selective advantagefor survival and proliferation of cancer cells (Levine and Puzio-
Kuter, 2010; Siegel and Zhu, 2009). Notably, altered metabolism
not only provides cancer cells with energy but also serves to
support synthesis of fatty acids, membrane lipids, and proteins
that are required for rapidly dividing cells (Menendez and Lupu,
2007). Lastly, equally important for survival of a transformed
cell and tumor formation and progression is the contribution of
the proteostatic system, which involves pathways that control
protein synthesis, quality control, and trafficking (Hotamisligil,
2010; Powers et al., 2009).
HCC induced within an established background of chronic
liver disease and cirrhosis after long latency (20–40 years) is
one of the most prevalent malignant cancers worldwide. The
transformation process underlying HCC development in hu-
mans, and many risk factors, including alcoholic use, chronic
infections with hepatitis B and C viruses, and nonalcoholic stea-
tohepatitis (NASH), which is a more severe form of nonalcoholic
fatty liver disease (NAFLD), are well defined (El-Serag and
Rudolph, 2007; Farazi and DePinho, 2006; Siegel and Zhu,
2009). Notably, NAFLD, a hepatic manifestation of metabolic
syndrome, affects nearly 25% of the US population and is
a fast-growing medical condition in terms of incidence due to
the fact that obesity and metabolic syndrome are becoming
epidemics worldwide. Despite recent progress, HCC is still
a disease with poor outcome and limited therapeutic options
(Spangenberg et al., 2009).
HCC development is well defined at the cellular level, begin-
ning with hyperplastic and dysplastic nodule formation in the
cirrhotic liver, and ultimately malignant conversion of a small
number of lesions. In contrast, the exact molecular mechanisms
accounting for hepatitis-driven cellular transformation are less
well understood. Supported by mouse genetic studies using
the procarcinogen diethylnitrosamine (DEN) or elimination of
functional NF-kB signaling, it was thought that chronic liver injury
caused by oxidative stress triggers inflammation, which drives
the compensatory proliferation of intact hepatocytes and liver
progenitors leading to initiation and progression of HCC
development (Luedde et al., 2007; Maeda et al., 2005). These
observations suggest that inhibition of compensatory liver cell
proliferation by modulating the inflammatory response may be
a realistic approach to reduce the risk of HCC.
Another critical hallmark of the pathogenesis of cancer in
general, and HCC in particular, is the contribution of metabolicCell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc. 91
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and glucose disposal and utilization. In fact, dysregulated
metabolism and exacerbated lipid biosynthesis and accumula-
tion emerge early in cancer development and accelerate cell
growth and transformation (Menendez and Lupu, 2007; Siegel
and Zhu, 2009). Recent reports, indicating that lipogenesis in
connection with the lipolytic release and remodeling of free fatty
acids promote high level of malignancy, suggest substantial
crosstalk between lipid metabolic pathways in cancer cells
(Nomura et al., 2010). Elucidating metabolic pathways that are
vital to the cancer pathogenesis and specifically assess to
what extent lipid accumulation in the injured liver may contribute
to HCC is of particular importance as an urgent need for devel-
opment of novel treatments of this disease.
Here we investigated a possible causal relationship between
alterations in hepatic energy and lipid metabolism, protein
homeostasis, metabolic syndrome, and HCC development. We
describe that HSF1, a key regulator of heat shock protein
(HSP) response, which is a protective mechanism conserved
among all eukaryotes and enhances survival and longevity of
organisms (Akerfelt et al., 2010; Hsu et al., 2003), is also critically
involved in HCC development by promoting metabolic adaptive
mechanisms for cancer development, including insulin signaling
and hepatic lipid accumulation.
RESULTS
Hsf1 Deletion Suppresses Chemical-Induced Liver
Tumorigenesis
To investigate the specific contribution of HSF1 to cancer path-
ogenesis, we conducted studies with procarcinogen DEN, which
induces HCC in 100% of male mice within 5–7 months.
DEN-induced HCC is a valid model for human HCC and repro-
duces some of the key pathological and histological features of
this cancer (Farazi and DePinho, 2006; Lee et al., 2004). Mice
of three genotypes, hsf1/, hsf1+/, and hsf1+/+, were injected
with DEN on postnatal day 14, and the tumor burden (number
and size) was determined 7 and 10 months later (Figures 1A
and 1B). While DEN-treated hsf1/ mice were free of liver
tumors and signs of apparent liver pathology, all hsf1+/+ control
littermates, referred as wild-type (WT), developed multiple
typical HCCs that contained clusters of cells staining strongly
positive for alpha-fetoprotein (a-FP) (Figure 1D), an established
liver tumor marker (Ariel et al., 1998). Western blot analysis at
different ages confirmed a-FP re-expression in livers of WT
mice bearing tumors, whereas it was absent in tumor-free
hsf1/ mice. Histological examination revealed the presence
of extensive liver pathology associated with severe steatosis in
DEN-treated WT mice (Figure 1C). Strikingly, the number of
tumors detected in hsf1+/mice and their size were dramatically
reduced compared to WT controls, indicating dose-dependent
effect of HSF1. Thus, HSF1 is required for efficient HCC induc-
tion and growth in response to DEN treatment.
Hsf1 Deletion Does Not Affect DEN-Induced Liver
Damage and Compensatory Proliferation during Early
Tumor Promotion
To further investigate the mechanisms for the remarkable resis-
tance of hsf1/ mice to HCC, we compared early (short-term)92 Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc.and late effects of DEN injection in WT and hsf1/ mice.
Short-term effects of DEN on liver integrity are marked by hepa-
tocyte death, increased cytokine production, and compensatory
hepatocyte proliferation and are proposed as good predictors of
the outcome of the disease (Farazi and DePinho, 2006; Karin and
Greten, 2005). WT and hsf1/ mice displayed comparable
hepatic injury after DEN injection (short-term), showing similar
levels of ALT and AST release and AST/ALT ratio, and no signif-
icant differences in the liver cell proliferation and apoptosis
(Figures 2A–2C). As expected, WT mice bearing (late stage)
tumors exhibited sustained increase in cellular proliferation,
apoptosis (and necrosis), and high levels of serum ALT and
AST and decreased ratio of AST/ALT, a useful parameter for
NAFLD (Sorbi et al., 1999). In contrast, hsf1/ mice recovered
remarkably from the early effects of DEN injection as revealed
by normalization of the liver pathology (see Figure S1A available
online). These differential effects on liver pathology appeared at
10 days and became more pronounced at 1 and 7 months post-
DEN injection.
Production of cytokines like IL-6, IL-1b, and TNF-a and hepa-
tocyte growth factor (HGF) by macrophages and Kupffer cells
triggered by substrates released from necrotic cells following
DEN injection appear to have a critical role in DEN-induced
HCC (Maeda et al., 2005). Indeed, activation of several cyto-
kines in early stage of DEN treatment was dramatically
induced, but overall detectable levels were comparable
between WT and hsf1/ mice (Figure 2D). This initial proin-
flammatory response persisted at a lower steady-state level
in WT mice through the progression stage; however, the cyto-
kine production in hsf1/ mice was not sustained and
decreased to barely detectable levels at 1 and 7 months of
age. Transcriptome analysis of the livers from hsf1/ versus
WT mice, without treatment, and 4 hr and 30 days after DEN
injection revealed that expression of several genes associated
with inflammation and immune response was upregulated.
However, no overt differences in the overall gene expression
pattern were observed between the genotypes (data not
shown). This indicates that tumor inhibition because of hsf1
deficiency cannot be attributed to the altered inflammatory
response during tumor initiation phase. Histological analysis
also confirmed that although the early effects of DEN (1 and
2 days) with respect to macrophage infiltration detected by
CD11b staining were indistinguishable between the genotypes,
hsf1/mice exhibited significantly fewer infiltrating cells in liver
at 10 days and 1 or 7 months after DEN administration (Fig-
ure S1B). Together, these results suggest that HSF1 function
is critical during tumor progression and that hsf1 deficiency
does not have apparent effects on the initial DEN-induced
hepatocyte death, cytokine secretion, and compensatory
proliferation.
Hsf1 Deletion Prevents DEN-Induced Hepatic Steatosis
A causal link between altered hepatic metabolism and cancer
progression has been proposed (Siegel and Zhu, 2009). Liver
damage induced by DEN administration is accompanied by
hepatic steatosis characterized by lipid deposition in hepato-
cytes. Histological examination of livers at 1 and 2 days after
DEN injection showed focal lipid accumulation by oil red O
staining (Figure 3). The extent of lipid deposition was
Figure 1. Deletion of hsf1 Inhibits DEN-Induced HCC Formation
(A) Representative macroscopic pictures of livers from WT, hsf1+/ and hsf1/mice 7 and 10 months after DEN injection. Arrowhead indicates tumor nodules.
m, month.
(B) Quantification of liver tumors inWT (n = 15), hsf1+/ (n = 7), and hsf1/ (n = 16) mice 7months after DEN injection. Scale bars represent mean ± SD. Statistical
significance is indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
(C) Histological analysis (H&E) of livers from WT, hsf1+/, and hsf1/ mice 7 months after DEN injection. Representative sections show no steatosis or HCC in
hsf1/ mice. WT and hsf1+/ mice display hepatic steatosis and HCC. Arrowheads depict HCC border (scale bar, 100 mm).
(D) Immunohistochemical analysis of liver sections for a-FP expression from WT and hsf1/mice at the indicated time points after DEN treatment at 14 days of
age (0). Positive staining is present in livers of both genotypes during early postnatal period that decreases and disappeared around 1.5 months of age. a-FP was
prominently re-expressed within HCCs developed in DEN-treatedWTmice (arrows). Western blot analysis of a-FP expression in liver extracts fromWT or hsf1/
mice at indicated time after DEN treatment is shown (right panel).
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post-DEN injection. However, starting at 2 months, livers of
WT mice displayed signs of lipid deposition that increased in
intensity during tumor progression and led to the development
of chronic liver disease with extensive steatosis at 7 and
10 months of age. In contrast, hsf1/ mice showed dramatic
inhibition of hepatic lipid accumulation and fatty liver disease
(Figure 3A). Consistently, levels of triglycerides and nonesteri-
fied fatty acids (NEFAs) in circulation and liver were significantlylower in hsf1/ mice (Figure 3B). Similarly, blood levels of total
cholesterol, low-density lipoprotein (LDL/VLDL), and high-
density lipoprotein (HDL) were reduced in hsf1/ mice in
both DEN-treated and untreated groups when compared to
WT mice (Figure 3C). However, the HDL/total cholesterol ratio
was the same between the genotypes. These results suggest
that HSF1 activation is critical in the development of HCC
by potentiating DEN-induced hepatic lipid biosynthesis and
deposition.Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc. 93
Figure 2. Comparable Levels of Liver
Damage and Compensatory Proliferation
during Early Stage of DEN-Induced HCC
between WT and hsf1–/– Mice
(A and B) Ki67 and TUNEL staining of liver sections
from WT or hsf1/ mice at the indicated time
points after DEN injection (left panels). Statistical
analysis of Ki67+ proliferating cells or TUNEL+
apoptotic hepatocytes per high-power field (HPF)
is presented (right panels). Scale bar, 20 mm (Ki67)
and 10 mm (TUNEL). Scale bars are mean ± SD
(n = 5 mice per group).
(C) Serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels. Scale
bars are mean ± SD; (n = 5 mice per group).
(D) Expression of cytokines in livers of DEN-
treated mice by real-time RT-PCR (upper panels).
Serum cytokine levels of untreated or DEN-
injected mice measured by ELISA (lower panels).
Scale bars are mean ± SD (n = 5 mice per group).
For all panels, statistical significance is indicated
(*p < 0.05, **p < 0.01, ***p < 0.001). d, day; m,
month. 0, WT or hsf1/ mice at 14 days of age
without DEN treatment.
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To investigate how HSF1 ablation counteracts changes in
hepatic lipid metabolism, we examined the effects of age on
growth, fat content, and lipid metabolism in hsf1/ and WT
mice (Figure 4). The rate at which hsf1/ mice increased body
weight on normal chow diet (CD) was significantly reduced
compared with WT mice; at 9 months of age the difference in
body weight was 25%. Moreover, WT mice displayed further
increase in body weight upon DEN treatment when compared
to untreated controls. No significant change in body weight
was observed between DEN-treated or untreated hsf1/ mice
(Figure 4A). Dissection of hsf1/ mice revealed marked reduc-
tion in epididymal white adipose tissue (WAT). When normalized
to body weight, total WAT was significantly reduced in hsf1/
compared to WT mice (Figure 4B). This decrease was specific
for fat, because the weight of other organs, like kidney and heart,
normalized to body weight did not show significant differences.
Notably, development of hepatic tumors inWTmice accounts for
the increase in liver weight in DEN-treatedWTmice as compared
to hsf1/ mice. Since food intake measured at 3 and94 Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc.7 months of age was comparable
between the genotypes, decrease in fat
accumulation was not due to hypophagia
(data not shown). Additionally, histolog-
ical analysis of epididymal fat cells at
7months of age was consistently smaller,
with an average 70% decrease in size in
hsf1/ mice compared to WT mice.
Depression of adipose tissue in hsf1/
micewas associated with strong downre-
gulation of adipose-specific genes like
PPARg1, PPARg2, C/EBPb, and FABP4
(aP2) (Figure S2).
The profound reduction in DEN-
induced hepatic steatosis in hsf1/mice may reflect the flexibility in the metabolic system to effi-
ciently compensate for enforced lipid accumulation by altering
hepatic lipid synthesis, lipolysis, uptake, secretion, or b-oxida-
tion of fatty acids. Therefore, we investigated whether hsf1 inac-
tivation negatively affects de novo lipogenesis in the liver and
thus inhibits hepatic fat accumulation (Figures 4C and 4D).
Expression of the lipogenic transcription factors, e.g., SREBP1c,
ChREBP, LXRa, or C/EBPb, was not significantly different
between normal (without DEN treatment) hsf1/ and WT mice
when measured at 7 months of age (Figure 4C). No significant
differences in C/EBPa or C/EBPb protein levels were detected
between the genotypes (data not shown). However, mRNA and
protein levels of PPARg1 or PPARg2 were found to be signifi-
cantly lower in liver of hsf1/ compared to age-matched WT
mice (Figures 4C and 4D). This result was also confirmed in
1.5-month-old mice (data not shown). Of interest, significant
increase in mRNA levels of these lipogenic transcription factors
was evident in DEN-treated WT mice, further supporting the
hypothesis that such changes regulate hepatic fat accumulation.
However, HSF1 ablation in DEN-treated mice inhibited mRNA
Figure 3. Hsf1 Deletion Prevents Chronic Hepatic Steatosis Induced by DEN Treatment
(A) Representative liver sections stained with oil red O at indicated times after DEN injection. Sections were counterstained with hematoxylin. 0, WT or hsf1/
mice at 14 days of age without DEN treatment. Scale bar, 10 mm.
(B) Levels of triglycerides and NEFAs in circulation and livers of untreated (Control) or DEN-treated mice at 7 months of age. Scale bars are mean ± SD (n = 5mice
per group). Statistical significance is indicated (*p < 0.05, **p < 0.01).
(C) Levels of cholesterol in HDL or LDL/VLDL and total cholesterol in the sera of untreated (control) or DEN-treatedmice at 7months of age. Scale bars aremean ±
SD (n = 5 mice per group). Statistical significance is indicated (*p < 0.05, **p < 0.01).
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of HSF1 also compromised DEN-induced mRNA levels of
SREBP1c and PPARg1 targets regulating lipid synthesis,
including FAS, ACL, and SCD1, while the mRNA level of ACC1
remained unchanged. Interestingly, mRNA level of ATGL,
a rate-limiting enzyme for triacylglycerol hydrolysis, was reduced
in hsf1/mice, providing evidence for inhibition of hepatic lipol-
ysis. The hepatic expression of ApoB and ApoE genes involved
in triglyceride secretion was not different between the genotypes
of untreated mice. In contrast, DEN treatment induced expres-
sion of both genes that was more pronounced in hsf1/ mice.
Additionally, in WT mice, DEN robustly induced expression of
CD36, a PPARg1 target gene involved in fatty acid uptake. But
lack of HSF1 entirely blunted this response. No differences inmRNA levels of the other genes related to lipid uptake, such as
LPL, FABP1, and FATP, were observed under untreated or
DEN-treated conditions. Finally, lack of HSF1 also impaired the
expression of genes related to fatty acid oxidation such as
PPARa, ACO, LCAD, or MCAD, which were robustly induced
following DEN treatment in theWTmice. Particularly, expression
of MCAD, a rate-determining enzyme in fatty acid oxidation, was
markedly reduced by lack of HSF1, while ACO expression was
slightly but not significantly affected. Together, these data indi-
cate that hsf1 deficiency prevents hepatic steatosis induced by
DEN through downmodulation of genes regulating lipid
synthesis, lipolysis, and fatty acid uptake. It is probable that
the observed reduction of fat synthesis is the reason for the
decreased hepatic lipid oxidation in hsf1/ mice.Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc. 95
Figure 4. Loss of HSF1 Protects from DEN-Induced Hepatic Steatosis through Inhibition of Lipid Synthesis
(A) Growth curves of untreated or DEN-treated WT and hsf1/mice on standard CD. Scale bars are mean ± SD (n = 10 mice per group). *p < 0.05 for WT-DEN-
treated compared to WT-untreated and **p < 0.01 for WT-untreated compared to hsf1/-untreated mice.
(B) Weight of epididymal adipose tissue (WAT) of 6- or 10-month-old WT and hsf1/mice, untreated (Control) or DEN-treated mice. Scale bars are mean ± SD
(n = 10 mice per group).
(C) Real-timeRT-PCR analysis of indicated genes in the liver of untreated or DEN-treated 7-month-oldWT or hsf1/mice. Data are presented as relative levels of
mRNA expression. Scale bars are mean ± SD (n = 5 mice per group). Sequences of the primers used are indicated in Table S1.
(D) Western blot analysis of liver extracts from 7-month-old untreated (DEN, control) or DEN-treated (+DEN) WT and hsf1/ mice using antibody against
PPARg. Quantification of protein expression level normalized to b-actin loading control, scale bars are mean ± SD (n = 8 mice per group) (right panels).
For (B) and (C), individual bars are defined in the inset on the upper right corner of the figure. For all panels, statistical significance is indicated (*p < 0.05, **p < 0.01,
***p < 0.001).
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Figure 5. Insulin Sensitivity and Glucose
Tolerance Are Enhanced in hsf1-Deficient
Mice
(A) GTT in 16 hr fasted untreated (top panels), or
DEN-treated (lower panels), WT (C), or hsf1/
(B) mice. Scale bars are mean ± SD (n = 8 mice
per group).
(B) ITT in 16 hr fasted untreated or DEN-treated
WT (C) or hsf1/ (B) mice, at 7 months of age.
Scale bars are mean ± SD (n = 8 mice per group).
(C) Blood glucose in fed (Fed) or 16 hr fasted (Fast)
untreated or DEN-treated mice at 1 or 7 months of
age. Scale bars are mean ± SD (n = 5 mice per
group).
(D) Plasma insulin levels determined by ELISA in
fed (Fed) or 16 hr-fasted (Fast) WT or hsf1/mice,
untreated or DEN treated, at the indicated ages.
Scale bars are mean ± SD (n = 5 mice per group).
(E) mRNA levels of G6Pase and PEPCK in the liver
of CD (Fed) or fasted (Fast) mice, untreated or DEN
treated, at 7 months of age. Scale bars are mean ±
SD (n = 4 mice per group).
Sequences of the primers used are indicated in
Table S1. For all panels, statistical significance is
indicated (*p < 0.05, **p < 0.01, ***p < 0.001).
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Tolerance in hsf1-Deficient Mice
Insulin signaling is a critical component in glucose homeostasis
and a major stimulus of hepatic metabolism (Herman and Kahn,
2006). Although no significant differences were seen in glucose
tolerance test (GTT) between the genotypes (without DEN treat-
ment) at 1 month of age, CD-fed hsf1/ mice assayed at 3 and
7 months of age exhibited a markedly improved glucose
tolerance compared to WT mice (Figure 5A). Of interest, DEN-
treated hsf1/ mice already exhibited a modest, but signifi-
cantly improved, glucose clearance measured by GTT at
1 month of age, and this effect was more pronounced at 3
and 7 months of age (Figure 5A). Insulin sensitivity, as measured
in the insulin tolerance test (ITT), was also enhanced in hsf1/
mice at 7 months of age. This effect was independent of DEN
treatment (Figure 5B). In addition, feeding blood glucose levels
did not differ between hsf1/ and WT mice assayed at different
ages. However, fasting glucose levels were slightly but
reproducibly reduced in hsf1/ mice compared to WT controls
at 7 months of age (Figure 5C). This effect was more
pronounced in DEN-treated mice. Consistent with enhancedCell Metabolism 14, 9insulin sensitivity, we also noted that
feeding plasma insulin levels in DEN-
treated or untreated hsf1/ mice were
significantly reduced as compared to
WT mice (Figure 5D). Of interest, mRNA
levels of key gluconeogenic enzymes,
PEPCK and G6Pase, were found to be
lower in the liver of hsf1/ mice, indi-
cating inhibition in hepatic glucose
production (Figure 5E).
To more sensitively test the positive
effects of hsf1 ablation on insulin sensi-
tivity, cohorts of hsf1/ and WT mice
were predisposed to diet-induced obesity and insulin resistance
by feeding with a high-fat diet (HFD) beginning at 4 weeks of age.
Consumption of HFD during the 20 week feeding period was
equivalent between the genotypes. As expected, WTmicemain-
tained on HFD gained substantial weight as compared to CD
feeding. In contrast, hsf1/ mice fed with CD or HFD had
body weight that did not significantly change after 10 weeks of
age and was significantly lower as compared to WT mice
(Figures S3A–S3C). HFD increased fat mass and hepatic lipid
accumulation in WT mice, but Hsf1/ mice were remarkably
resistant (Figures S3D and S3E). In addition, CD- or HFD-fed
hsf1/mice exhibited equivalent insulin sensitivity as indicated
by glucose clearance in the GTT or ITT, which, however, was
greater compared toWTmice (Figures S3F andS3G). Consistent
with these results, under HFD feeding hsf1/ mice maintained
lower fasting insulin and glucose levels compared to WT
controls. In addition, while HFD produced a blunted insulin
response in WT mice, the hsf1/ mice exhibited normal
insulin-stimulated AKT-signaling in liver and muscle (Figures
S3H and S3I). Taken together, these results show that insulin
sensitivity is increased as a result of hsf1 deficiency and is1–103, July 6, 2011 ª2011 Elsevier Inc. 97
Cell Metabolism
Regulation of Hepatic Metabolism and HCC by HSF1reflected in reduced hepatic lipid accumulation irrespective of
CD or HFD feeding.
HSF1 Deficiency Enhances Insulin-Induced Activation
and Signaling
Insulin is well known to stimulate glucose disposal by increasing
glucose uptake in peripheral tissues and also driving de novo
lipogenesis and steatosis, and in the fed state it is a major anti-
lipolytic hormone (Duncan et al., 2007; Kersten, 2001). In this
context, one surprising result of our study was that hsf1 defi-
ciency increased insulin sensitivity but decreased de novo lipo-
genesis, thus preventing hepatic steatosis. To further explore
this issue, we investigated the activation of insulin receptor (IR)
and downstream signaling pathways in the liver of hsf1/ versus
WTmice at 7months of age. Interestingly, we detected amarked
increase in mRNA and protein levels of IRb and associated
insulin receptor substrates (IRSs), IRS1 and IRS2, in livers of
untreated or DEN-treated hsf1/ mice compared to WT coun-
terparts (Figure 6A and Figure S4). In addition, insulin-like growth
factor-I receptor (IGF-IR) level in the liver remained unaltered
(Figure S4).
Next we evaluated that insulin-induced phosphorylation of IRb
tyrosine (p-Y) or IRb subunit (Y1158/Y1162/Y1163) was
enhanced in hsf1/ mice compared to WT controls (Figures
6A and 6B). In addition, insulin stimulation resulted in a significant
increase in p-Y-IRS1 in livers of both genotypes, but hsf1/
mice exhibited much higher levels of total and p-Y-IRS1 (Fig-
ure 6B). Next, we examined the insulin-stimulated phosphoryla-
tion of IRS1 (p-IRS1) at putative inhibitory sites at residue S612
and S636/639. No significant difference was observed in relative
p-IRS1(S612) levels, but interestingly hsf1/ mice exhibited
a reduced basal and insulin-stimulated ratio of p-IRS1(S636/
S639)/total IRS1 compared to WT controls. Consistent with the
above findings, hsf1/ mice displayed increased p-Y-IRS1
and associated p85 levels compared to WT counterparts (Fig-
ure 6B). These results suggest that the improved insulin sensi-
tivity in hsf1/ mice can be ascribed primarily to increased
IRb and IRS levels rather than to a particular pattern of IRS
protein modification by phosphorylation. Expectedly, insulin
stimulated AKT(S473) and to lesser extent AKT(T308) phosphor-
ylation were significantly higher in the liver of hsf1/ mice
compared to WT controls (Figure 6C). The p-AKT increase in
the liver of mutant mice was accompanied by an enhanced
increase in phosphorylation and inactivation of AKT substrates
Foxo1 (S256 and S319), GSK3a (S21), GSK3b (S9), and AS160
(T642) (regulator of GLUT4 trafficking predominantly expressed
in muscles and adipose tissues) compared to WT controls. In
comparison, hsf1/ mice displayed slightly better response to
injected insulin with respect to GSK3 phosphorylation, although
this did not reach to a significance. The dramatic increase in
insulin-stimulated p-AKT (S473) in livers of hsf1/ mice did
not yield the expected level of mTORC1 activation revealed by
reduced phosphorylation of p70SK1 (T389) and S6R (S240/
244), which are major mTOR targets (Figure 6C). Moreover, the
level of p-mTOR (S2448) mediated by p70SK1 (Foster and Fin-
gar, 2010) was found to be significantly lower in hsf1/ mice
than in controls, consistent with the attenuation of p70SK1
activity. Notably, inhibition of mTOR pathway in hsf1/ mice
was partial, as indicated by the residual phosphorylation levels98 Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc.of p70SK1 and S6R proteins. Further, insulin-induced signaling
under fasting conditions did not impair phosphorylation of
mTOR target 4E-BP1 (T37/46 and S65) in the livers of hsf1/
mice compared to WT controls (data not shown), suggesting
the translational levels were not dramatically impaired. Thus,
the differential sensitivity to insulin stimulation in the mutant
mice depends on increased IR and IRS levels. This leads to
enhanced PI3K/AKT pathway activation, rapid phosphorylation,
and attenuation of the activity of AKT substrates (Foxo1, GSK3,
AS160), which inhibit glucose production but increased utiliza-
tion. Enhanced insulin-induced signaling was also observed in
livers of hsf1/ mice at 2 months of age, indicating that HSF1
has a central role in insulin sensitivity at the early stage of HCC
development (data not shown).
Loss of HSF1 Decreases Hepatic Lipogenesis
by Promoting Insulin Signaling in Association
with AMP-Kinase Activation
AMPK, which senses cellular energy status, is a negative regu-
lator of mTOR activation, and there is evidence that AMPK acti-
vation may prevent insulin resistance (Canto and Auwerx, 2010;
Shaw, 2009; Zhang et al., 2009). We found that livers of WTmice
expressed a relatively low basal level of p-AMPK(T172) that was
not altered by insulin treatment (Figure 7A). In contrast, livers of
hsf1/mice had significantly higher basal levels of p-AMPK and
insulin induced AMPK activation to a much greater level
compared to WT counterparts.
To evaluate the functional consequences of AMPK activation,
we analyzed AMPK substrates. Activated AMPK by phosphory-
lating mitochondrial enzyme ACC(S79) decreases its activity and
inhibits fatty acid synthesis (ACC1) and promotes fatty acid
oxidation (ACC2). Moreover, AMPK-mediated phosphorylation
of raptor (S792) decreases mTORC1 activity and of hormone-
sensitive lipase (HSL) (S565) inhibits HSL-mediated lipolysis
(Gwinn et al., 2008; Watt et al., 2006). Notably, during periods
of increased energy demands (e.g., fasting), the rate of lipolysis
is increased. Although lipolysis is regulated by a complex
process involving several hormone-regulated lipases, the phos-
phorylation of HSL by activated AMPK that attenuates its activity
is believed to play a critical role in regulating lipid homeostasis in
relation to energy demand. Our results show that phosphoryla-
tion levels of ACC (S79), raptor (S792), and HSL (S565) are signif-
icantly higher in the livers of hsf1/ mice compared to WT
controls (Figure 7A and Figure S5). Injection of insulin in fasted
animals stimulated p-HSL (S565) in both genotypes, but livers
of hsf1/ mice exhibited a higher basal level of p-HSL that
was strongly induced to a much higher level compared to
controls (Figure S5). Similarly, insulin-induced p-AMPK was
enhanced in muscles of hsf1/ mice (data not shown). Of
interest, insulin-stimulated signaling in liver of WT mice induced
HSF1 activation, which was detected by the slower HSF1 elec-
trophoretic mobility due to increased phosphorylation (arrows
in Figure 7A).
As HSF1 regulates components of the proteostatic system
and protein-folding quality control, we evaluated whether HSF1
senses nutrient availability. Physiological protein-induced stress
can be created in liver by feeding the mice after a fasting period;
this process not only activates cellular stressors by inducing
protein synthesis in the endoplasmic reticulum (ER) and cytosol
Figure 6. Enhanced Insulin Receptor Signaling in the Absence of HSF1
(A) Immunoblot analyses of basal and insulin-stimulated total and p-Y-IR, total and p-Ser (S) IRS1, and total IRS2 levels in livers of 7-month-old WT and hsf1/
mice. Mice were fasted for 16 hr and i.p. injected with saline or insulin 0.75 mU/g. Liver extracts prepared from individual mice 10 min after insulin injection and
blots were quantified by densitometry. Level of phosphorylated protein normalized to total level was expressed as relative fold increase to control (WT without
insulin) that was arbitrarily set at 1 (100%). Scale bars are mean ± SD (n = 5 mice per group).
(B) Liver extracts prepared 10min after insulin or saline injection from individual WT or hsf1/mice were immunoprecipitated using IRS1 antibody and processed
for immunoblot analysis with antibodies to p-Tyr (p-Y), IRS-1, or PI3K p85. ns, nonspecific antibody (negative control) (left panel). Ratio of p-Tyr (p-Y) IRS1 to total
IRS1 signal intensity is indicated. Whole liver extracts of mice in the left panel were probed with antibody to p-Y, IRS1, PI3K p85, or b-actin. Relative molecular
sizes corresponding to p-Y IRS1 and p-Y IR are indicated (right panel).
(C) Activation of AKT andmTOR signaling in the liver extracts from (A) was examined by immunoblot analysis using indicated antibodies. Quantification of blots is
presented (right panels). Scale bars are mean ± SD (n = 5 mice per group).
For all panels, statistical significance is indicated (*p < 0.05, **p < 0.01, ***p < 0.001). Bars indicate WT (filled) or hsf1/ (open) mice.
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Figure 7. HSF1 Promotes Hepatic Meta-
bolic Adaptation by Modulating Proteosta-
sis and Influences Energy Metabolic Path-
ways in Response to Nutrient Availability
and Insulin Stimulation
(A) Increased insulin sensitivity in hsf1/ mice
results in enhanced AMPK activation: shown are
immunoblot analyses of basal and insulin-stimu-
lated p-AMPK levels in livers of WT and hsf1/
mice. Seven-month-old mice were fasted for 16 hr
and i.p. injected with saline or insulin (0.75 mU/g).
Liver extracts prepared 10 min after insulin or
saline injection were examined, and blots were
quantified (right panels). Level of p-AMPK or
p-ACC normalized to total protein level was
expressed as relative fold increase to control (WT
without insulin). Scale bars are mean ± SD (n = 5
mice per group).
(B) Expression of HSF1, AMPK, and target genes
under nutrient available conditions. Shown are
representative western blots of liver extracts from
7-month-old mice, fasted for 24 hr or refed ad
libitum for 3 hr, using the indicated antibodies. The
ratio of p-AMPK or p-ACC normalized to total
protein level is given. Shown is real-time RT-PCR
analysis of genes that encode for HSPs in liver of
hsf1/ or WT mice (lower panels). Data are pre-
sented as relative mRNA expression. Scale bars
are mean ± SD (n = 3–5 mice per group).
In all panels, bars indicate WT (filled) or hsf1/
(open) mice. Statistical significance is indicated
(*p < 0.05, **p < 0.01, ***p < 0.001).
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the potential contribution of HSF1 to proteostasis and hepatic
metabolism. Under fasting conditions, HSF1 activity was present
at low levels. However, under feeding or refeeding conditions,
we observed an increase in HSF1 activity (indicated by arrows)
leading to expression of hsp genes (Figure 7B). This result
suggests that the metabolic load created by refeeding led to
HSF1 activation. We next determined that the p-AMPK/AMPK
ratio was significantly higher in the livers of hsf1/ mice than
control mice of 7 months of age (Figure 7B). However,
p-AMPK level did not fluctuate during nutrient cycle. Of note,
basal p-AMPK level was high in fed mutant mice, obscuring
nutrient-induced p-AMPK under fasting or refeeding conditions.
Consistent with this result, although the p-ACC (S79) levels
exhibited only modest fluctuation in livers of fasted and
postprandial mice, hsf1/ mice exhibited a significantly higher
p-ACC/ACC ratio compared to WT mice indicating enhanced
AMPK activity (Figures 7B). This increased AMPK activation to
nutrient availability was also observed in the liver of hsf1/
mice at 2 months of age (data not shown).
To investigate the functional significance of AMPK activation
in the context of hepatic metabolism and carcinogen-induced
liver tumorigenesis, we examined the phosphorylation status
of AMPK and AMPK substrates in untreated or DEN-treated
mice. First, we noted that under CD feeding, p-AMPK levels
increased in aged mice, but the livers of hsf1/ mice exhibited
significantly higher p-AMPK/AMPK ratio than WT controls
(Figure S6A). This was accompanied by increased p-ACC,
p-Raptor, and p-HSL in mutant mice, indicating enhanced
sensitivity to energy metabolism. Of note, p-AMPK levels in100 Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc.aged WT mice did not yield the expected increase in p-ACC
level, indicating age-dependent decline in AMPK activity as re-
ported (Reznick et al., 2007). Further, we observed that hsf1/
mice compared to WT controls exhibited a much higher basal
level of p-AKT (S473) throughout the life that is consistent
with enhanced insulin signaling. In summary, the age of onset
of elevated AMPK activation correlates with the timing of
increased AKT signaling in hsf1/ mice. Next, we checked
the expression levels of AMPK and AMPK substrates in the liver
of CD-fed DEN-treated mice. We observed that hsf1/ mice
exhibited small but significant increase in p-AMPK level
compared to WT controls, albeit p-AMPK levels were lower in
DEN-treated animals (Figure S6B). Overall, the p-ACC level
was also slightly but reproducibly increased in mutant mice
compared to WT controls, consistent with the p-AMPK levels.
The level of p-HMG-CoA reductase (S872) (HMG-CR), a rate-
determining enzyme in cholesterol synthesis and AMPK target,
which decreases enzyme activity, did not differ significantly
between the genotypes (Figure S6B). Compared to WT control,
DEN-treated hsf1/ mice exhibited significantly decreased
level of FAS, a central molecule in lipogenesis and a known
transcriptional target of SREBP-1c in response to feeding and
insulin signaling. The fact that mRNA level of SREBP-1c was
found to be reduced in DEN-treated hsf1/ mice (Figure 4C)
may explain the decreased FAS protein level. Further, there
was not a significant difference in AMPK-mediated p-HSL level
in CD-fed mice. However, DEN-treated WT mice exhibited
markedly decreased p-HSL that was less pronounced in
hsf1/ mice (Figure S6). This result suggests that inhibition
of HSL activity by elevated p-HSL might be responsible for
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treated hsf1/ mice (Figure 3).
Taken together, these results suggest a link between energy
metabolism and proteostasis driven by HSF1 that enable meta-
bolic adaptation to nutrient availability under physiological
conditions. Hsf1 deficiency enhances insulin signaling, causing
a more severe energy deficit especially under nutrient availability
and promotion of AMPK activation. Activation of AMPK in
absence of HSF1 changes the metabolic balance in the liver
toward utilization of carbohydrates as an energy source and
suppression of lipid synthesis, thus generating metabolic condi-
tions where malignant transformation induced by carcinogens is
inhibited.
DISCUSSION
Transcriptional regulators that respond to stress also influence
survival and longevity of organisms. HSF1 plays a central role
in regulating heat shock response, which is an adaptive
response by organisms to protect against environmental insults
and enhances survival and longevity (Akerfelt et al., 2010; Hsu
et al., 2003). However, increased HSF1-mediated resistance to
stress also has growth-promoting effects toward specific tumor
types that are detrimental to the normal life span of organisms.
As reported previously, loss of HSF1 negatively impacts tumor-
igenesis driven by p53 or Ras mutations (Dai et al., 2007; Min
et al., 2007). Since HSF1 does not function as a classic onco-
gene or tumor repressor, it was suggested that increased resis-
tance to proteotoxic stress induced by HSF1may support tumor
initiation and growth by enabling cells to accommodate genetic
alterations that occur during malignancy. Although HSF1
impacts a large array of cellular functions that are altered during
malignancy, including translation, ribosome biogenesis, and
glucose metabolism (Hahn et al., 2004), specific mechanisms
by which HSF1 may support growth of specific tumors are not
well understood. Here, we have demonstrated that HSF1 has
detrimental effects on survival of the organism by potentiating
perturbations in hepatic metabolism caused by carcinogens
that lead to hepatic steatosis and HCC. The data indicate that
genetic inactivation of HSF1 results in the upregulation of protec-
tive mechanisms against metabolic stress induced by risk
factors for chronic liver disease and cirrhosis that can lead to
HCC development after several decades.
One interesting result in the present study is that hsf1 defi-
ciency corrects DEN-induced hepatic metabolic abnormalities
associated with fat accumulation by coactivating two opposing
signaling pathways: increased insulin sensitivity with improved
insulin signal transduction, and activated AMPK in response to
energy depletion and insulin stimulation (model in Figure S7). In
liver, insulin, through activation of IR and AKT, suppresses
hepatic gluconeogenesis by negatively regulating Foxo1, PCG-
1a, and CRTC2 (Dentin et al., 2007; Gross et al., 2008; Li et al.,
2007). Of interest, we observed repression of hepatic gluconeo-
genesis in liver of DEN-treated hsf1/ mice that correlates with
lower mRNA levels of PEPCK and G6Pase, most likely due to
enhanced insulin signaling. However, insulin also stimulates lipid
accumulation through activation of AKT, which positively regu-
lates de novo anabolic lipid metabolism by promoting glucose
uptake, glycolysis, and expression of genes involved in lipidbiosynthesis (such as SREBP1c). In addition, insulin promotes
mTORC1 activation that upregulates ribosomal biogenesis and
protein translation, but also induction of SREBP-1 and expres-
sion of target genes involved in lipid synthesis (Laplante and
Sabatini, 2009). On the other hand, AMPK activation induced
in response to ATP depletion in the cell can blunt the anabolic
effects of insulin in lipid biogenesis, reducing hepatic lipid depo-
sition by promoting fatty acid oxidation and impairing SREBP-1c
expression and activation. Negative regulation of mTORC1 by
AMPK can increase insulin sensitivity by repressing p70S6K1
phosphorylation and inactivation of IRS1 (Shaw, 2009; Zhang
et al., 2009).
Based on this information and our data, we propose a model
(Figure S7) whereby loss of HSF1 increases basal level of IR
and IRS1, sensitizing cells to insulin stimulation. This causes
rapid glucose utilization preferentially inmuscles but also in other
tissues via GLUT4 translocation to cell membrane, a process
negatively regulated by AS160. Limited glucose availability
under insulin stimulation, particularly in the liver of mutant mice
in which glucose production is impaired, may cause transient
energy deficit resulting in AMPK activation. Further, enhanced
AKT signaling can promote protein synthesis and protein glyco-
sylation that can consume ATP, causing transient ATP depletion
and AMPK activation (Fang et al., 2010). Although this mecha-
nism has been proposed to promote aerobic glycolysis and
tumor cell growth, hsf1-deficient cells appear to be resistant to
undergo the glycolytic shift characteristic of cancer cells; thus
the tumor-promoting effects of AKT signaling on cellular glucose
metabolism are blunted by HSF1 deficiency (Dai et al., 2007).
The mechanism by which HSF1 exerts this effect remains
elusive. On the other hand, AMPK activation inhibits lipogenesis
and thus protects from hepatic steatosis, diminishing insulin-
induced effects on lipid synthesis. In principle it is possible that
HSF1 may exert effects on lipid metabolism through transcrip-
tional control of lipogenic factors such as PPARg, a key regulator
of adipogenesis, but this possibility is unlikely, since both
primary mouse embryonic fibroblasts from WT and hsf1/
mice were equally capable of inducing adipogenesis under pro-
differentiative conditions, giving rise to lipid-accumulating cells
that express markers of differentiated adipocytes including
PPARg (data not shown). Altogether we propose that enhanced
insulin sensitivity in association with AMPK activation is possibly
the driving force for the lean phenotype of the hsf1/ mice and
striking resistance to DEN-induced hepatic steatosis and HCC
development. However, our work does not preclude the contri-
bution of inflammation triggered by excessive lipid deposition
in cancer progression in our model. Further, the contribution of
other organs such as adipose tissue and muscle to altered
metabolism in hsf1/ mice cannot be excluded. This aspect
requires further investigation because our data indicate that
key prolipogenic transcription factors are also significantly
reduced in adipose tissues in the absence of HSF1, indicating
its broader role in lipid metabolism.
Another interesting observation in our study is the link estab-
lished between proteostasis and hepatic metabolism. We antic-
ipate that HSF1 activity regulated by nutrient availability
supports malignant transformation through promoting proteo-
static pathways and thus metabolic adaptations toward cancer
development. In general, protein quality control pathways areCell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc. 101
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synthesis in ER and cytosol under normal nutrient conditions.
We presume that the feedback mechanism in our model by
which HSF1 target molecules attenuate the IR-IRS1-AKT
signaling pathway after insulin stimulation helps to restore meta-
bolic homeostasis, averting pathological overstimulation of
insulin signaling. Although the underlying mechanism is
unknown, we propose that HSF1 and its major targets (HSPs)
may be critical negative regulators of IR and IRS1 expression
by modulating the ubiquitin-proteasome degradation system
as reported (Mayer and Belsham, 2010; Zhande et al., 2002).
Notably, we have shown that hsf1 deletion in cell culture inhibits
this pathway and stabilizes p53, and perhaps other proteins (Jin
et al., 2009). However, direct effect of HSF1 on transcriptional
repression of IR and IRS1 expression cannot also be ruled out,
and our data support such a mechanism. In DEN-induced
HCC, this HSF1-dependent mechanism may participate to
increase insulin resistance and thus tumor formation.
Taken together, the results suggest that HSF1 may have
a central role along with other signaling components in HCC
development by modulating proteostasis and metabolic path-
ways and may be an important drug target in the treatment of
this disease.EXPERIMENTAL PROCEDURES
Animals, Liver Tumor Induction, and Analysis
Hsf1/ mice were previously reported (Zhang et al., 2002). Both hsf1/ and
hsf1+/+ control littermates were of mixed C57BL/6-129SvPas F1 genetic back-
ground. Animal care and experiments were performed in accordance with the
guidelines of Institutional Animal Care and Use Committee and National Insti-
tutes of Health (NIH) guidelines.
A single dose of DEN (25 mg/kg body weight) (Sigma) was injected into
14-day-old male mice intraperitoneally (i.p.) to initiate tumor formation, and
animals were euthanized at different ages as indicated. Livers were removed
and analyzed for presence of HCCs using a dissecting microscope, and indi-
vidual lobes were snap frozen in OCT or paraffin embedded and subjected to
histological and immunochemical analyses. For early response analyses, mice
were sacrificed at 4 hr or 1, 2, 10, or 30 days post-DEN administration. For
HCC analysis, mice were euthanized at 7 or 10 months after DEN treatment,
andmouseweight, liver weight, number of tumors per liver (percent tumor inci-
dence), maximal tumor size (mm), and percent tumor area/liver were
determined.Glucose and Insulin Tolerance Tests
Glucose and insulin tolerance tests were carried out following overnight fasting
(16 hr). Animals were injected i.p. with either 2 mg/g glucose or 0.75 mU/g
insulin. Blood glucose was assayed from the tail vein using an automated
glucose monitor (Bayer HealthCare LLC, IN, USA).Liver Enzymes and Insulin Assays
Serum ALT and AST levels were detected using Liquid Reagent Kit according
to the manufacturer’s instructions (Pointe Scientific Inc., MI, USA). Triglycer-
ides and NEFA concentrations were determined using an acyl-CoA oxidase-
based colorimetric kit (Wako Biochemicals USA Inc., Richmond, VA, USA).
Serum insulin level was determined using ELISA kit (Calbiochem, Spring
Valley, CA, USA). Serum cholesterol in HDL or LDL/VLDL and total cholesterol
levels were assayed using detection kit (BioVision, Mountain View, CA, USA).Serum Cytokine Assays
Concentrations of serum IL-6 and TNF-a were determined using an immuno-
assay kit (eBioscience, Inc., San Diego, CA, USA).102 Cell Metabolism 14, 91–103, July 6, 2011 ª2011 Elsevier Inc.Western Blot, Histology and Immunohistochemistry,
and Real-Time PCR
These assays were performed by standard procedures. For more information,
see the Supplemental Experimental Procedures.
Statistical Consideration
All experiments were performedwith at least 3–20mice. Data are presented as
mean ± SD. Statistical significance between experimental groups was as-
sessed using Student’s t test, and p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.cmet.2011.03.025.
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